(Q38365804)

2 September 2017

1 reference

title

Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars (English)

1 reference

2 September 2017

1 reference

Stefan Mühlebach

1

1 reference

PubMed ID

25723097

2 September 2017

Gerrit Borchard

series ordinal

2

1 reference

PubMed ID

25723097

2 September 2017

Selcan Yildiz

series ordinal

3

1 reference

2 September 2017

1 March 2015

1 reference

2 September 2017

1 reference

2 September 2017

10

1 reference

2 September 2017

4

1 reference

2 September 2017

659-674

1 reference

Do nanomedicines require novel safety assessments to ensure their safety for long-term human use?

2 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Safety assessment of nanomaterials: implications for nanomedicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Different pharmaceutical products need similar terminology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Challenges in development of nanoparticle-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Relating nanomaterial properties and microbial toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Toxicity of TiO(2) nanoparticles to cladocerans, algae, rotifers and plants - effects of size and crystalline structure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Particle-size-dependent toxicity and immunogenic activity of mesoporous silica-based adjuvants for tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Emerging trends of nanomedicine--an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

The Relationship between fenestrations, sieve plates and rafts in liver sinusoidal endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Nanoparticles and the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Nanotoxicity: oxidative stress mediated toxicity of metal and metal oxide nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Nanotechnology in agri-food sector

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Nanotherapeutics--product development along the "nanomaterial" discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Metallothionein: the multipurpose protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Use of parenteral iron products and serious anaphylactic-type reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Nanoparticle iron medicinal products - Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Do two intravenous iron sucrose preparations have the same efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Switchability of neoral and equoral according to Food and Drug Administration rules and regulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

Long term in vivo biotransformation of iron oxide nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.189

21 January 2018

Identifiers

DOI

10.2217/NNM.14.189

1 reference

2 September 2017

1 reference

PubMed ID

25723097